Product logins

Find logins to all Clarivate products below.


Retinal Vein Occlusion – Epidemiology – Epidemiology Dashboard

Clarivate’s Epidemiology’s coverage of retinal vein occlusion comprises epidemiological estimates of key patient populations. We report the prevalence of retinal vein occlusion for each country as well as annualized case counts projected to the national population.

Most patient populations are forecast over a period of ten years for the other countries covered in this report. For the mature markets, the patient population is forecast over a period of 20 years.

Clarivate Epidemiology’s retinal vein occlusion forecast will answer the following question:

  • How will demographic trends, such as population aging and improving life expectancy, affect the epidemiology of retinal vein occlusion over the forecast period?

All forecast data are available on the Clarivate Insights Platform in tabular format, with options to download to MS Excel. All populations are accompanied by a comprehensive description of the methods and data sources used, with hyperlinks to external sources. A summary evidence table generated as part of our systematic review of the epidemiological literature is also provided for full transparency into research and methods.

In addition to the total number of cases for each forecast year,Clarivate’s Epidemiology provides at least ten years of forecast data for the following retinal vein occlusion subpopulations:

  • Total prevalent RVO cases by subtype scheme.
  • Total prevalent RVO cases with comorbid macular edema.

Related Market Assessment Reports

Report
Immunoglobulin A Nephropathy – Access & Reimbursement – Access & Reimbursement – Immunoglobulin A Nephropathy (US)
The U.S. IgA nephropathy (IgAN) therapy market predominantly comprises supportive treatments such as RAAS inhibitors, SGLT-2 inhibitors, immunosuppressants, and/or diuretics. The FDA’s acceptance…
Report
Heart Failure – Current Treatment – Treatment Algorithms: Claims Data Analysis – Heart Failure with Preserved Ejection Fraction (US)
Heart failure with preserved ejection fraction (HFpEF) accounts for approximately half of all chronic heart failure cases. Even though physicians’ understanding of the disease’s pathophysiology…
Report
Axial Spondyloarthritis – Current Treatment – Treatment Algorithms: Claims Data Analysis – Ankylosing Spondylitis (US)
Ankylosing spondylitis (AS) is a chronic inflammatory disease that primarily affects the sacroiliac joints and the axial skeleton, leading to persistent back pain and stiffness. The main treatment…
Report
Biosimilars – Forecast – Ophthalmology
In 2023, sales of branded biologics in ophthalmology exceeded $9.2 billion in the major pharmaceutical markets under study (United States, EU5, and Japan). Throughout our 2023-2033 forecast period…
Report
Obesity / Overweight – Current Treatment – Treatment Algorithms: Claims Data Analysis – Obesity / Overweight (US)
As the prevalence of obesity rises, the demand for safe and effective treatments increases. Therapies mimicking GLP-1 and GIP peptides—hormones that regulate appetite and energy metabolism—have…